Kirkland, Washington-based Cardiac Dimensions develops minimally invasive treatments for heart failure with functional mitral regurgitation (FMR). That includes the Carillon Mitral Contour System, for which the company has the ongoing EMPOWER trial. Its new CMO served as an advisor on that trial.
“I’ve seen the compelling clinical evidence on Carillon therapy from Europe and look forward to helping the team expand the supportive body of evidence for this intriguing technology with the U.S. pivotal EMPOWER trial,” said Shreenivas. “I have always been energized by my work with emerging technologies that fill an unmet clinical need and am excited by the opportunity this therapy presents to enhance the lives of heart failure patients in a way that isn’t possible today.”
More about the new CMO at C…